公开(公告)号：US20130237482A1

公开(公告)日：2013-09-12

申请号：US13676248

申请日：2012-11-14

申请人： Kazuhisa TSURUTA ,  Yoshikazu AOKI ,  Yutaka OSAWA ,  Inder KAUL

发明人： Kazuhisa TSURUTA ,  Yoshikazu AOKI ,  Yutaka OSAWA ,  Inder KAUL

IPC分类号： A61K38/57

CPC分类号： A61K38/366 ,  A61K9/0019 ,  A61K38/00 ,  A61K38/177 ,  A61K38/57 ,  C12N15/09

摘要： A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.

公开(公告)号：US20130244926A1

公开(公告)日：2013-09-19

申请号：US13897100

申请日：2013-05-17

申请人： KAZUHISA TSURUTA ,  YOSHIKAZU AOKI ,  YUTAKA OSAWA ,  INDER KAUL

发明人： KAZUHISA TSURUTA ,  YOSHIKAZU AOKI ,  YUTAKA OSAWA ,  INDER KAUL

IPC分类号： A61K38/36

CPC分类号： A61K38/366 ,  A61K9/0019 ,  A61K38/00 ,  A61K38/177 ,  A61K38/57 ,  C12N15/09

摘要： A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.

公开(公告)号：US08772239B2

公开(公告)日：2014-07-08

申请号：US13676248

申请日：2012-11-14

申请人： Kazuhisa Tsuruta ,  Yoshikazu Aoki ,  Yutaka Osawa ,  Inder Kaul

发明人： Kazuhisa Tsuruta ,  Yoshikazu Aoki ,  Yutaka Osawa ,  Inder Kaul

IPC分类号： A61K38/36 ,  A61K38/57 ,  C12N15/09 ,  A61K38/00

CPC分类号： A61K38/366 ,  A61K9/0019 ,  A61K38/00 ,  A61K38/177 ,  A61K38/57 ,  C12N15/09

摘要： A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.

摘要翻译： 一种用于治疗和/或改善伴有一种或多种器官功能障碍的严重败血症患者的败血症的药物，其中从所述患者获得的血浆样本的国际标准化比率（INR）大于1.4，其包括 血栓调节素作为活性成分。